EDIT
Editas Medicine Inc

17,116
Mkt Cap
$198.17M
Volume
2.2M
52W High
$4.54
52W Low
$0.9101
PE Ratio
-0.85
EDIT Fundamentals
Price
$2.03
Prev Close
$2.09
Open
$2.10
50D MA
$2.35
Beta
2.02
Avg. Volume
1.76M
EPS (Annual)
-$2.88
P/B
14.07
Rev/Employee
$131,357.72
Loading...
Loading...
News
all
press releases
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - What's Next?
Editas Medicine (NASDAQ:EDIT) Share Price Passes Below 50-Day Moving Average - What's Next...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat.com...
MarketBeat·17d ago
News Placeholder
Cathie Wood shells out $1.3 million on biotech stock
On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...
TheStreet.com·20d ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9% - Should You Sell?
Editas Medicine (NASDAQ:EDIT) Shares Down 2.9% - Should You Sell...
MarketBeat·20d ago
News Placeholder
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago
News Placeholder
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities...
MarketBeat·1mo ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold...
MarketBeat·2mo ago
News Placeholder
Insider Selling: Editas Medicine (NASDAQ:EDIT) CEO Sells 5,603 Shares of Stock
Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...
MarketBeat·2mo ago
News Placeholder
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving Average - Time to Sell?
Editas Medicine (NASDAQ:EDIT) Shares Cross Below Fifty Day Moving Average - Should You Sell...
MarketBeat·2mo ago
News Placeholder
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
Zacks·2mo ago
<
1
2
...
>

Latest EDIT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.